Ad  Wall Street Zen

16 Best Stocks to Buy Today

Our proven quant model, the Zen Ratings, has averaged a +32.52% annual return. We combine that with Steve Reitmeister's 44 years of investing experience to pinpoint the 16 best stocks for the year ahead in his coveted Zen Investor portfolio.

Discover Zen Investor & Top 16 Stocks Now >

Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billion

By Michael Erman and Manas Mishra (Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older therapies expire later this decade. Karuna’s experimental schizophrenia drug, called KarXT, should drive sales through the late 2020s…

Read More